Pharmagreen Biotech Inc. (PHBI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pharmagreen Biotech Inc. (PHBI) trades at $0.334. Pharmagreen Biotech Inc. focuses on producing starter plantlets for the CBD hemp and medical cannabis industries. The company aims to serve the growing demand for high-quality cannabis cultivation materials. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for PHBI: PHBI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PHBI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PHBI: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Pharmagreen Biotech Inc. (PHBI) Healthcare & Pipeline Overview
Pharmagreen Biotech Inc., operating in the biotech sciences sector, specializes in providing starter plantlets to the CBD hemp and medical cannabis industries. The company is positioned to capitalize on the increasing demand for cannabis cultivation materials, focusing on the production and distribution of high-quality starter plants.
What Is the Investment Thesis for PHBI?
Pharmagreen Biotech Inc. presents a speculative investment opportunity within the cannabis industry, focusing on the production of starter plantlets. The company's negative P/E ratio of -2.08 and a negative profit margin of -16.3% indicate current challenges in achieving profitability. However, the increasing demand for CBD hemp and medical cannabis could drive future revenue growth. A key value driver is the company's ability to scale its plantlet production and distribution capabilities. Growth catalysts include potential partnerships with cannabis cultivators and expansion into new geographic markets. The company's high beta of 1.77 suggests significant volatility, making it a higher-risk investment. Successful execution of its growth strategy and improvements in operational efficiency are crucial for achieving profitability and delivering shareholder value. Investors should carefully consider the risks associated with the OTC market and the company's current financial performance.
Based on FMP financials and quantitative analysis
PHBI Key Highlights
Pharmagreen Biotech Inc. operates in the biotech sciences sector, focusing on the production of starter plantlets for the CBD hemp and medical cannabis industries.
- The company's market capitalization is $0.00B, indicating a small market presence.
- Pharmagreen Biotech Inc. has a negative P/E ratio of -2.08, reflecting current losses.
- The company's profit margin is -16.3%, indicating challenges in achieving profitability.
- Pharmagreen Biotech Inc. has a beta of 1.77, suggesting higher volatility compared to the market.
Who Are PHBI's Competitors?
PHBI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PHBI's Key Strengths?
Specialized focus on starter plantlets.
- Emphasis on quality control and genetic consistency.
- Potential for proprietary plant genetics.
- Strategic partnerships with cultivators.
What Are PHBI's Weaknesses?
Negative P/E ratio and profit margin.
- Small market capitalization.
- Reliance on the cannabis industry.
- Limited geographic diversification.
What Could Drive PHBI Stock Higher?
Increasing demand for CBD hemp and medical cannabis.
- Potential partnerships with cannabis cultivators.
- Expansion into new geographic markets.
- Development of proprietary plant genetics.
- Licensing of plantlet production technology.
What Are the Key Risks for PHBI?
Financial-distress signal — its Altman Z-Score of -48.40 sits in the distress zone (elevated bankruptcy risk).
- Regulatory changes in the cannabis industry.
- Competition from other plantlet suppliers.
- Fluctuations in cannabis prices.
- Economic downturns affecting consumer spending.
- Limited regulatory oversight as an OTC stock.
What Are the Growth Opportunities for PHBI?
- Expansion into New Geographic Markets: Pharmagreen Biotech Inc. has the opportunity to expand its operations into new geographic markets where cannabis cultivation is legal and growing. This expansion could involve establishing new production facilities or partnering with local cultivators to distribute its starter plantlets. The global cannabis market is projected to reach $47 billion by 2027, providing a significant opportunity for Pharmagreen Biotech to increase its market share through geographic diversification. Timeline: 2026-2028.
- Strategic Partnerships with Cannabis Cultivators: Pharmagreen Biotech Inc. can pursue strategic partnerships with cannabis cultivators to secure long-term supply agreements and expand its customer base. These partnerships could involve providing cultivators with exclusive access to its high-quality starter plantlets in exchange for guaranteed purchase volumes. The market for cannabis cultivation inputs is estimated at $5 billion annually, offering a substantial opportunity for Pharmagreen Biotech to generate revenue through strategic alliances. Timeline: Ongoing.
- Development of Proprietary Plant Genetics: Pharmagreen Biotech Inc. can invest in the development of proprietary plant genetics to create unique and high-performing starter plantlets. This could involve using advanced breeding techniques to develop plants with enhanced CBD or THC content, improved disease resistance, or higher yields. The market for proprietary cannabis genetics is growing rapidly, with cultivators seeking access to superior plant varieties that can enhance their profitability. Timeline: 2027-2029.
- Vertical Integration into Cannabis Cultivation: Pharmagreen Biotech Inc. could consider vertical integration into cannabis cultivation to capture a larger share of the value chain. This could involve establishing its own cultivation facilities to grow and process cannabis using its starter plantlets. The vertically integrated cannabis market is estimated at $10 billion annually, providing an opportunity for Pharmagreen Biotech to increase its revenue and profitability through vertical expansion. Timeline: 2028-2030.
- Licensing of Plantlet Production Technology: Pharmagreen Biotech Inc. can license its plantlet production technology to other companies in the cannabis industry. This could involve providing companies with the know-how and equipment to produce their own starter plantlets using Pharmagreen Biotech's proprietary methods. The market for cannabis technology licensing is growing as companies seek to improve their cultivation processes and reduce costs. Timeline: 2027-2029.
What Are PHBI's Competitive Advantages?
- Specialized focus on starter plantlets for CBD hemp and medical cannabis.
- Emphasis on genetic consistency and quality control in plantlet production.
- Potential for proprietary plant genetics and cultivation technologies.
- Strategic partnerships with cannabis cultivators.
What Does PHBI Do?
Pharmagreen Biotech Inc., established in 2007 and headquartered in Coquitlam, Canada, operates as a biotech sciences solutions company. It focuses on the burgeoning CBD hemp and medical cannabis industries. The company's core business revolves around the production of starter plantlets, which are essential for cannabis cultivation. These plantlets provide a foundation for growers aiming to produce high-quality CBD hemp and medical cannabis. Pharmagreen Biotech aims to supply cultivators with reliable and genetically sound starting materials, thereby supporting the overall quality and consistency of the final cannabis products. The company's strategic focus on starter plantlets allows it to cater to a specific niche within the broader cannabis market, positioning itself as a key supplier for cultivators seeking quality inputs. Pharmagreen Biotech's operations are primarily based in Canada, with potential for expansion into other regions as the cannabis industry continues to evolve globally. The company's business model emphasizes quality control and genetic consistency in its plantlet production processes, ensuring that cultivators receive reliable and high-performing starter materials. Pharmagreen Biotech's focus on starter plantlets allows it to play a crucial role in the cannabis supply chain, contributing to the overall growth and development of the industry.
What Products and Services Does PHBI Offer?
- Produces starter plantlets for CBD hemp.
- Produces starter plantlets for medical cannabis.
- Provides biotech sciences solutions for cannabis cultivation.
- Supplies cultivators with high-quality cannabis starting materials.
- Focuses on genetic consistency in plantlet production.
- Aims to support the quality and consistency of cannabis products.
How Does PHBI Make Money?
- Generates revenue through the sale of starter plantlets to cannabis cultivators.
- Focuses on producing high-quality and genetically consistent plantlets.
- Aims to establish long-term supply agreements with cultivators.
- Potentially licenses plantlet production technology to other companies.
What Industry Does PHBI Operate In?
Pharmagreen Biotech Inc. operates within the rapidly evolving cannabis industry, specifically targeting the CBD hemp and medical cannabis segments. The market is characterized by increasing demand for high-quality cannabis products and cultivation inputs. The competitive landscape includes companies like ALID, APPB, CBDY, CNNA, and CPMD, which are also involved in various aspects of the cannabis industry. Pharmagreen Biotech's focus on starter plantlets positions it as a supplier to cultivators, differentiating it from companies that focus on finished cannabis products. The industry is subject to regulatory changes and evolving consumer preferences, which can impact market dynamics and growth opportunities.
Who Are PHBI's Key Customers?
- CBD hemp cultivators.
- Medical cannabis cultivators.
- Companies involved in cannabis cultivation.
- Businesses seeking high-quality starter plantlets.
Pharmagreen Biotech Inc. Financial Trajectory
Pharmagreen Biotech Inc. (PHBI) reported $912K in revenue for Q1 2026, a decline of 73.4% compared to the prior quarter. The company recorded a net loss of $65K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, PHBI averaged $-0.00 in diluted EPS.
Company Profile
Pharmagreen Biotech Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Coquitlam, CA. The company is led by CEO Peter Wojcik. PHBI has traded publicly since 2018.
Key Financial Metrics
Return on equity for Pharmagreen Biotech Inc. stands at 21.1%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -3.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Pharmagreen Biotech Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -48.40 places it in the distress zone, a signal of elevated financial risk.
PHBI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized focus on starter plantlets.
- Emphasis on quality control and genetic consistency.
- Potential for proprietary plant genetics.
- Strategic partnerships with cultivators.
Bear Case
- Negative P/E ratio and profit margin.
- Small market capitalization.
- Reliance on the cannabis industry.
- Limited geographic diversification.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $911,699 | -$65,141 | -$0.0001 |
| Q4 2025 | $3M | -$1M | -$0.0017 |
| Q3 2025 | $588 | -$138,332 | -$0.0002 |
| Q2 2025 | $335 | $45,582 | $0.0001 |
Based on FMP financials and quantitative analysis
PHBI Latest News
No recent news available for PHBI.
PHBI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PHBI.
Price Targets
Wall Street price target analysis for PHBI.
PHBI MoonshotScore
What does this score mean?
The MoonshotScore rates PHBI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Peter Wojcik
CEO
Peter Wojcik serves as the CEO of Pharmagreen Biotech Inc. His background includes experience in the biotech and cannabis industries. He has been involved in various aspects of the company's operations, including strategic planning, business development, and investor relations. Peter Wojcik's leadership aims to drive the company's growth and expansion in the CBD hemp and medical cannabis markets. His expertise in the biotech sector is expected to guide Pharmagreen Biotech in developing innovative solutions for cannabis cultivation.
Track Record: Under Peter Wojcik's leadership, Pharmagreen Biotech Inc. has focused on establishing itself as a supplier of starter plantlets for the cannabis industry. Key milestones include expanding the company's production capacity and forming partnerships with cannabis cultivators. Peter Wojcik has also overseen the development of the company's proprietary plantlet production methods. His strategic decisions aim to position Pharmagreen Biotech as a key player in the cannabis supply chain.
PHBI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Pharmagreen Biotech Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may be subject to greater price volatility. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and the potential for fraud or manipulation. Investors should conduct thorough due diligence and be aware of the risks involved before investing in Pharmagreen Biotech Inc.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher price volatility compared to exchange-listed stocks.
- Risk of delisting or suspension of trading.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive position.
- Review the company's legal and regulatory compliance.
- Evaluate the company's risk factors and potential liabilities.
- Monitor the company's trading volume and price activity.
- Consult with a financial advisor before investing.
- Company has been in operation since 2007.
- Focuses on a specific niche within the cannabis industry.
- CEO with experience in the biotech sector.
- Partnerships with cannabis cultivators (if any).
- Efforts to develop proprietary plantlet production methods.
What Investors Ask About Pharmagreen Biotech Inc. (PHBI) — Healthcare
What does Pharmagreen Biotech Inc. do?
Pharmagreen Biotech Inc. is a biotech sciences solutions company focused on the production of starter plantlets for the CBD hemp and medical cannabis industries. The company supplies cultivators with high-quality and genetically consistent starting materials, aiming to support the overall quality and consistency of cannabis products.
What are the main risks for PHBI?
The main risks for Pharmagreen Biotech Inc. include regulatory changes in the cannabis industry, competition from other plantlet suppliers, and fluctuations in cannabis prices. The company's reliance on the cannabis industry exposes it to market volatility and shifts in consumer preferences.
What are the key factors to evaluate for PHBI?
Evaluate PHBI on fundamentals, analyst consensus, and risk factors. Pharmagreen Biotech Inc. presents a speculative investment opportunity within the cannabis industry, focusing on the production of starter plantlets. Not financial advice.
How frequently does PHBI data refresh on this page?
PHBI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PHBI's recent stock price performance?
Pharmagreen Biotech Inc. (PHBI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on starter plantlets. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PHBI overvalued or undervalued right now?
Pharmagreen Biotech Inc. (PHBI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PHBI before investing?
Before investing in Pharmagreen Biotech Inc. (PHBI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding PHBI to a portfolio?
Key strength of Pharmagreen Biotech Inc. (PHBI): Specialized focus on starter plantlets. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending for PHBI, limiting the depth of insights.
- Financial data is limited, affecting the accuracy of the analysis.
- OTC market investments carry higher risks.